Literature DB >> 16441247

Outcome of short-term antiepileptic treatment in patients with solitary cerebral cysticercus granuloma.

A Verma1, S Misra.   

Abstract

OBJECTIVES: The duration of antiepileptic drug (AED) therapy in cases of solitary cerebral cysticercus granuloma (SCCG) presents a major dilemma and the efficacy of short-term (6 months) vs long-term (2 years) AED therapy has been studied.
MATERIALS AND METHODS: Prospective randomized study of short-term vs long-term AED treatment with SCCG has been undertaken. A total of 206 subjects with new onset seizures with SCCG were randomized into two groups: group A (98 patients) were treated for 6 months and group B (108 patients) were treated for 2 years with AED therapy. The patients were evaluated periodically during and at least 18 months after the tapering of drugs.
RESULTS: Partial seizures with or without secondary generalization has been found to be the commonest manifestation occurring in 80.6% of patients with SCCG. In group A 66.3% and in group B 57.4% patients showed complete resolution of computerized tomographic lesion and rest had punctated residual calcification. Statistically, no significant difference in the recurrence of seizures was found in two groups with disappearance of lesion but the difference between calcified residua and complete resolution subset was significant. In patients having residual calcification, 42.2% in group A and 21.7% in group B had recurrence of seizures and the difference was statistically significant (Z = 1.97, P < 0.05).
CONCLUSIONS: The study revealed that SCCG with epilepsy is a benign self-limiting disease. A longer duration of therapy is not warranted in patients having total resolution of lesion. Calcified lesion was found to be the most common cause of recurrence of seizures. Higher recurrence rate was observed in short-term therapy in patients having calcified lesions and may require long-term AED treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441247     DOI: 10.1111/j.1600-0404.2005.00538.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

Review 1.  Conservative management of neurocysticercosis in a patient with hematopoietic stem cell transplantation: a case report and review.

Authors:  S Purvey; K Lu; S K Mukkamalla; P Anandi; B Dumitriu; S Kranick; D A Hammoud; E O'Connell; A L Oh; J Barrett; S Mahanty; M Battiwalla
Journal:  Transpl Infect Dis       Date:  2015-06-01       Impact factor: 2.228

Review 2.  Antiepileptic drugs for seizure control in people with neurocysticercosis.

Authors:  Marta Frackowiak; Monika Sharma; Tejinder Singh; Amrith Mathew; Benedict D Michael
Journal:  Cochrane Database Syst Rev       Date:  2019-10-14

3.  Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.

Authors:  Arturo Carpio; Mindy Chang; Hongbin Zhang; Matthew L Romo; Alex Jaramillo; W Allen Hauser; Elizabeth A Kelvin
Journal:  Epilepsia       Date:  2019-07-29       Impact factor: 5.864

4.  A diagnostic and therapeutic scheme for a solitary cysticercus granuloma.

Authors:  G Singh; V Rajshekhar; J M K Murthy; S Prabhakar; M Modi; N Khandelwal; H H Garcia
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

Review 5.  Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.

Authors:  Willem M Otte; Monika Singla; Josemir W Sander; Gagandeep Singh
Journal:  Neurology       Date:  2012-12-26       Impact factor: 9.910

6.  Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  A Clinton White; Christina M Coyle; Vedantam Rajshekhar; Gagandeep Singh; W Allen Hauser; Aaron Mohanty; Hector H Garcia; Theodore E Nash
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

Review 7.  Antiepileptic drugs for seizure control in people with neurocysticercosis.

Authors:  Dean Walton; Hannah Castell; Ceryce Collie; Greta Karen Wood; Monika Sharma; Tejinder Singh; Benedict D Michael
Journal:  Cochrane Database Syst Rev       Date:  2021-11-01

8.  Management of provoked seizure.

Authors:  Usha Kant Misra; Jayantee Kalita
Journal:  Ann Indian Acad Neurol       Date:  2011-01       Impact factor: 1.383

9.  The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations.

Authors:  Annette Abraham; Javier A Bustos; Hélène Carabin; Robert de Meijere; Priyadarshi S Sahu; Vedantam Rajshekhar; Gagandeep Singh; A Clinton White; Peter L Chiodini; Sarah Gabriël; Mamoun Homeida; Theodore Nash; Bernard Ngowi; Xiao Nong Zhou; Christina Coyle; Hector H Garcia; Andrea S Winkler
Journal:  PLoS Negl Trop Dis       Date:  2021-03-31

10.  Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  A Clinton White; Christina M Coyle; Vedantam Rajshekhar; Gagandeep Singh; W Allen Hauser; Aaron Mohanty; Hector H Garcia; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2018-04       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.